Moderna and Merck's Personalized Cancer Vaccine Shows Promise in Melanoma Trial
Moderna and Merck's experimental personalized mRNA cancer vaccine has shown promising results in its first late-stage trial for melanoma, causing Moderna's stock to double. This breakthrough marks a significant step forward in cancer treatment, with the vaccine tailored specifically for each patient.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (79/100)Sources
Moderna shares soar 60% on melanoma vaccine trial success
Company’s melanoma cancer vaccine being developed with Merck
Read full article →Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Read full article →Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
By Jaimy Lee
Read full article →Moderna, Merck rise after late-stage trial win for mRNA cancer therapy
Read full article →Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success
Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company. The study met its primary endpoint by showing that the cancer ...
By Tyler Durden
Read full article →
